Загрузка...
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma
The combination of clarithromycin, lenalidomide, and dexamethasone (BiRd) was evaluated as therapy for treatment-naive symptomatic multiple myeloma (MM), with overall response at 2 years of 90%. We reviewed the long-term follow-up of initial BiRd therapy. Seventy-two patients were given dexamethason...
Сохранить в:
| Главные авторы: | , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society of Hematology
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3596960/ https://ncbi.nlm.nih.gov/pubmed/23299315 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-08-448563 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|